{"id":"https://openalex.org/W3085290259","doi":null,"title":"Cost-Effectiveness and Value of Perfect Information Analyses for Bruton's Tyrosine Kinase Inhibitors for Patients with Relapsed or Refractory Mantle Cell Lymphoma in the United States","display_name":"Cost-Effectiveness and Value of Perfect Information Analyses for Bruton's Tyrosine Kinase Inhibitors for Patients with Relapsed or Refractory Mantle Cell Lymphoma in the United States","publication_year":2020,"publication_date":"2020-01-01","ids":{"openalex":"https://openalex.org/W3085290259","mag":"3085290259"},"language":"en","primary_location":{"id":"pmh:oai:repository.arizona.edu:10150/641746","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10150/641746","pdf_url":"http://hdl.handle.net/10150/641746","source":{"id":"https://openalex.org/S4306400271","display_name":"UA Campus Repository (The University of Arizona)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I138006243","host_organization_name":"University of Arizona","host_organization_lineage":["https://openalex.org/I138006243"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Electronic Thesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://hdl.handle.net/10150/641746","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011900688","display_name":"Neda Al Rawashdh","orcid":"https://orcid.org/0009-0009-6840-3360","observed_orcids":["https://orcid.org/0009-0009-6840-3360"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Neda Al Rawashdh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5011900688"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9003999829292297,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9003999829292297,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.04780000075697899,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.017400000244379044,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.972000002861023},{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/zanubrutinib","display_name":"zanubrutinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":1.0},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9179999828338623},{"id":"https://openalex.org/keywords/value-of-perfect-information","display_name":"value of perfect information","score":0.921999990940094},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6809999942779541},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9279999732971191},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.7129999995231628},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.628000020980835}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.7765130996704102},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.7440874576568604},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.5738131999969482},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5432800054550171},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5281593799591064},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49498695135116577},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4740407466888428},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4605085253715515},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40881070494651794},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3555082678794861},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2594183087348938},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.1309935450553894},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.11841502785682678},{"id":"https://openalex.org/C191897082","wikidata":"https://www.wikidata.org/wiki/Q11467","display_name":"Metallurgy","level":1,"score":0.0860876739025116},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:repository.arizona.edu:10150/641746","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10150/641746","pdf_url":"http://hdl.handle.net/10150/641746","source":{"id":"https://openalex.org/S4306400271","display_name":"UA Campus Repository (The University of Arizona)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I138006243","host_organization_name":"University of Arizona","host_organization_lineage":["https://openalex.org/I138006243"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Electronic Thesis"},{"id":"mag:3085290259","doi":null,"is_oa":false,"landing_page_url":"https://repository.arizona.edu/handle/10150/641746","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:repository.arizona.edu:10150/641746","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10150/641746","pdf_url":"http://hdl.handle.net/10150/641746","source":{"id":"https://openalex.org/S4306400271","display_name":"UA Campus Repository (The University of Arizona)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I138006243","host_organization_name":"University of Arizona","host_organization_lineage":["https://openalex.org/I138006243"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Electronic Thesis"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9074000120162964,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3085290259.pdf","grobid_xml":"https://content.openalex.org/works/W3085290259.grobid-xml"},"referenced_works_count":49,"referenced_works":["https://openalex.org/W1247968195","https://openalex.org/W1605423339","https://openalex.org/W1982967337","https://openalex.org/W1991285311","https://openalex.org/W1994277369","https://openalex.org/W1998861351","https://openalex.org/W2009957924","https://openalex.org/W2017628547","https://openalex.org/W2036266060","https://openalex.org/W2047445129","https://openalex.org/W2058365975","https://openalex.org/W2064323879","https://openalex.org/W2065061530","https://openalex.org/W2072839232","https://openalex.org/W2088438184","https://openalex.org/W2111975215","https://openalex.org/W2112023756","https://openalex.org/W2118498521","https://openalex.org/W2130669641","https://openalex.org/W2158037744","https://openalex.org/W2165832667","https://openalex.org/W2172024692","https://openalex.org/W2190884983","https://openalex.org/W2315507109","https://openalex.org/W2505332531","https://openalex.org/W2535831594","https://openalex.org/W2553911513","https://openalex.org/W2617308136","https://openalex.org/W2760089233","https://openalex.org/W2763767393","https://openalex.org/W2766024739","https://openalex.org/W2769717282","https://openalex.org/W2770172979","https://openalex.org/W2771732863","https://openalex.org/W2774522106","https://openalex.org/W2799661816","https://openalex.org/W2807176624","https://openalex.org/W2894826441","https://openalex.org/W2905411389","https://openalex.org/W2937859579","https://openalex.org/W2943412515","https://openalex.org/W2945874655","https://openalex.org/W2952307708","https://openalex.org/W2963774393","https://openalex.org/W2975040754","https://openalex.org/W2976534553","https://openalex.org/W2983390781","https://openalex.org/W2989391086","https://openalex.org/W2996460130"],"related_works":["https://openalex.org/W4220717213","https://openalex.org/W3097043578","https://openalex.org/W2906559274","https://openalex.org/W4416507980","https://openalex.org/W7207724488","https://openalex.org/W4391842236","https://openalex.org/W4390127511","https://openalex.org/W4310124567","https://openalex.org/W6939908221","https://openalex.org/W3027381497"],"abstract_inverted_index":{"Objectives:":[0],"This":[1],"study":[2],"aimed":[3],"to":[4,59,70,74,145,367],"(1)":[5],"evaluate":[6],"the":[7,22,53,61,66,79,118,135,156,170,185,232,247,278,293,299,303,373,389,402,441,526],"cost-effectiveness":[8,249],"of":[9,55,65,82,271,308,324,338,371,375,407,427,444,449,458,500,504,530],"second-generation":[10,48],"Bruton\u2019s":[11],"tyrosine":[12],"kinase":[13],"(BTK)":[14],"inhibitors,":[15],"including":[16],"acalabrutinib":[17,112,241,315,354,465,515],"and":[18,63,69,94,105,184,207,211,224,236,246,252,261,283,321,335,355,361,378,385,396,432,437,472,474,528],"zanubrutinib,":[19,377,431],"compared":[20,342,469],"with":[21,30,85,99,115,240,302,314,331,343,357,454,470,496],"first-generation":[23],"BTK":[24,49],"inhibitor":[25],"(ibrutinib)":[26],"in":[27,258,306,317,479,502],"treating":[28],"patients":[29],"relapsed":[31],"or":[32,107,113,242],"refractory":[33],"mantle":[34],"cell":[35],"lymphoma":[36],"(R/R":[37],"MCL)":[38],"using":[39],"existing":[40],"evidence":[41,68,84,391],"from":[42,117,141,155,277,298],"phase":[43,157,171,186,491],"I/II":[44,187,492],"clinical":[45,159,173,188,393],"trials":[46],"for":[47,89,128,168,182,197,229,401,421,429,511],"inhibitors;":[50],"(2)":[51],"assess":[52],"value":[54,81,270,370],"additional":[56,83,91,422],"information":[57,273],"analyses":[58,264],"identify":[60],"gap":[62],"uncertainty":[64,405,425,456,501],"current":[67],"prioritize":[71],"future":[72],"studies":[73,523],"resolve":[75],"uncertainty;":[76],"(3)":[77],"compare":[78,525],"expected":[80,86,269],"opportunity":[87],"costs":[88,212,347,426],"performing":[90],"studies.":[92],"Methods":[93],"Materials:":[95],"A":[96],"Markov":[97],"model":[98],"two":[100,136],"health":[101,126,137,208,285,477,505,519],"states":[102,138],"(progression-free":[103],"[PF]":[104],"progression":[106],"death)":[108],"was":[109,201,275,329,415,452],"established,":[110],"comparing":[111,292,353],"zanubrutinib":[114,243,328,356,473],"ibrutinib":[116,358,379,433,471],"United":[119],"States":[120],"(US)":[121],"payer":[122],"perspective.":[123],"To":[124],"simulate":[125],"outcomes":[127,210,398,478],"each":[129,230,307],"treatment":[130,296],"regimen,":[131],"transition":[132],"probabilities":[133,374],"between":[134],"were":[139,213,256,359,434],"derived":[140],"parametric":[142],"distributions":[143],"fitted":[144],"Kaplan\u2013Meier":[146],"(KM)":[147],"curves":[148,154],"based":[149,485],"on":[150,486],"PF":[151],"survival":[152],"(PFS)":[153],"III":[158],"trial":[160,174,189],"reported":[161,175,190],"by":[162,176,191,291,518],"Dreyling":[163],"et":[164,178,193],"al.":[165,179,194],"(Lancet":[166,180],"2016)":[167],"ibrutinib,":[169,245],"II":[172],"Wang":[177],"2018)":[181],"acalabrutinib,":[183,376,430],"Tam":[192],"(Blood":[195],"2019)":[196],"zanubrutinib.":[198],"The":[199,219,268,345,424,461],"analysis":[200],"conducted":[202],"over":[203,244],"a":[204,365,419,497],"lifetime":[205],"horizon,":[206],"utility":[209,397],"discounted":[214],"at":[215],"3.5%":[216],"per":[217,348,413],"year.":[218],"PFS":[220,225,234,237,319,322,333,336,349],"life":[221,445],"years":[222],"(LYs)":[223],"quality-adjusted":[226],"LYs":[227,235,320,334],"(QALYs)":[228],"treatment,":[231],"incremental":[233,248,318,332,346],"QALYs":[238,323,337,410],"gained":[239,351],"ratio":[250,254],"(ICER)":[251],"cost-utility":[253],"(ICUR)":[255],"estimated":[257],"both":[259],"base":[260],"probabilistic":[262],"sensitivity":[263],"(PSA;":[265],"100,000":[266,309],"simulations).":[267],"perfect":[272],"(EVPI)":[274],"calculated":[276],"net":[279,284],"monetary":[280],"benefit":[281,286],"(NMB)":[282],"(NHB)":[287],"that":[288,464,507,524],"are":[289,382,494,533],"forgone,":[290],"overall":[294],"optimal":[295,304],"resulting":[297],"PSA":[300,310],"ICURs":[301],"strategy":[305],"simulations.":[311],"Results:":[312],"Treatment":[313],"resulted":[316],"(3.40,":[325],"2.66)":[326],"while":[327,440],"associated":[330,453,495],"(2.21,":[339],"1.71)":[340],"when":[341,352],"ibrutinib.":[344],"QALY":[350],"$41,744":[360],"$37,813,":[362],"respectively.":[363,387],"For":[364],"willingness":[366],"pay":[368],"(WTP)":[369],"$100,000,":[372],"being":[380],"cost-effective":[381,468],"50%,":[383],"34%,":[384],"16%,":[386],"Using":[388],"available":[390],"regarding":[392],"efficacy,":[394],"costs,":[395],"as":[399],"inputs":[400],"model,":[403],"an":[404,455],"cost":[406,457],"$92,473":[408],"(NHB=0.93":[409],"is":[411,466,516],"forgone)":[412],"patient":[414],"obtained,":[416],"which":[417,489],"implies":[418],"need":[420],"research.":[423],"effectiveness":[428],"$66,709,":[435],"$53,916,":[436],"$984,":[438],"respectively,":[439],"health-related":[442],"quality":[443],"(HRQoL)":[446],"(disutility":[447],"values)":[448],"adverse":[450],"events":[451],"$85,949.":[459],"Conclusions:":[460],"results":[462],"demonstrate":[463],"more":[467],"greatly":[475],"improves":[476],"R/R":[480],"MCL":[481],"patients.":[482],"However,":[483],"decisions":[484],"this":[487],"analysis,":[488],"used":[490],"trials,":[493],"high":[498],"level":[499],"terms":[503],"benefits":[506],"may":[508],"be":[509],"forgone":[510],"some":[512],"populations":[513],"if":[514],"adopted":[517],"insurance":[520],"companies.":[521],"Future":[522],"efficacy":[527],"HRQoL":[529],"these":[531],"agents":[532],"recommended.":[534]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-09-21T00:00:00"}